Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura A Williams

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
American Journal of Nephrology|October 5, 2007
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysisEdward A Ross, Jin Tian, Hanna Abboud, et al.
Pharmacogenetics|April 30, 2004
Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokineticsKatherine D Furman, David R Grimm, Toby Mueller, et al.
Clinical and Experimental Pharmacology & Physiology|February 1, 2006
Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agentsLee C Preusser, Ryan M Fryer, Armin Gerhardt, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 8, 2010
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind studyEli M Roth, James M McKenney, Maureen T Kelly, et al.
Cardiovascular Drugs and Therapy|October 19, 2010
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 studyEli M Roth, Robert S Rosenson, Dawn M Carlson, et al.
American Journal of Nephrology|March 18, 2006
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4Hanna Abboud, Daniel Coyne, Olgierd Smolenski, et al.
Frontiers in Allergy|August 26, 2024
Immunotherapy with biodegradable nanoparticles encapsulating the oligosaccharide galactose-alpha-1,3-galactose enhance immune tolerance against alpha-gal sensitization in a murine model of alpha-gal syndromeMichael N Saunders, Claudia M Rival, Mahua Mandal, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 19, 2014
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)Michael H Davidson, Robert S Rosenson, Kevin C Maki, et al.
Clinical Pharmacology and Therapeutics|June 5, 2004
CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levelsDavid A Katz, David R Grimm, Steven C Cassar, et al.
Advanced Healthcare Materials|September 28, 2023
Building-Block Size Mediates Microporous Annealed Particle Hydrogel Tube Microenvironment Following Spinal Cord InjuryBrian C Ross, Robert N Kent, Michael N Saunders, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
American Journal of Nephrology|October 5, 2007
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysisEdward A Ross, Jin Tian, Hanna Abboud, et al.
Pharmacogenetics|April 30, 2004
Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokineticsKatherine D Furman, David R Grimm, Toby Mueller, et al.
Clinical and Experimental Pharmacology & Physiology|February 1, 2006
Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agentsLee C Preusser, Ryan M Fryer, Armin Gerhardt, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 8, 2010
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind studyEli M Roth, James M McKenney, Maureen T Kelly, et al.
Cardiovascular Drugs and Therapy|October 19, 2010
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 studyEli M Roth, Robert S Rosenson, Dawn M Carlson, et al.
American Journal of Nephrology|March 18, 2006
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4Hanna Abboud, Daniel Coyne, Olgierd Smolenski, et al.
Frontiers in Allergy|August 26, 2024
Immunotherapy with biodegradable nanoparticles encapsulating the oligosaccharide galactose-alpha-1,3-galactose enhance immune tolerance against alpha-gal sensitization in a murine model of alpha-gal syndromeMichael N Saunders, Claudia M Rival, Mahua Mandal, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 19, 2014
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)Michael H Davidson, Robert S Rosenson, Kevin C Maki, et al.
Clinical Pharmacology and Therapeutics|June 5, 2004
CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levelsDavid A Katz, David R Grimm, Steven C Cassar, et al.
Advanced Healthcare Materials|September 28, 2023
Building-Block Size Mediates Microporous Annealed Particle Hydrogel Tube Microenvironment Following Spinal Cord InjuryBrian C Ross, Robert N Kent, Michael N Saunders, et al.
Pageof 4